DND-41 In Vitro Genome Sequencing Assay

This assay is to provide DND-41-based In Vitro Genome Sequencing Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

DND-41

Human

DND-41 was established from the peripheral blood of 13-year-old boy with T-acute lymphoblastic leukemia (T-ALL; type III cortical) in 1977; described to carry CDKN2B (p15INK4B) and CDKN2A (p16INK4A) deletions and TP53 (p53)mutation.

Acute Lymphoblastic Leukemia; ALL

Oncology

In Vitro Genome Sequencing Assay

DND-41-cell based In Vitro Genome Sequencing Assay

Genome sequencing is the most accurate and informative method used to identify gene mutations in basic biological and clinical research.

Genome Alteration Assays

Aberrant or somatic mutations are more commonly found in the DNA of cancer cells compared to normal cells. There is an equilibrium that exists between DNA damage and repair in normal cells. However, in cancer cells these events are disturbed, resulting in mutations and genomic instability. Genomic instability in cancer cells causes chromosomal aberrations, microsatellite instability, aneuploidy and uncontrolled gene amplifications and genetic instability in cancer cells are mainly due to point mutations or chromosomal aberrations such as insertions, deletions and translocation, resulting in mutated proteins.